According to the announcement of Buchang Pharmaceutical, the 2026 edition of the “National Essential Drug Catalogue” came into effect on September 1, and a total of 104 products from the company and its holding subsidiaries were included, including 2 new exclusive varieties from the holding subsidiary. They are Kang Gynecitis capsules, a wholly-owned subsidiary, and Mudan granules from a holding subsidiary, respectively. At this stage, it is not possible to quantify the specific impact of this matter on business performance, but it will have a positive impact in the long term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.